Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Principal Inclusion Criteria:~* Subject must be 18 to 75 years of age.~* Documented physician-diagnosed asthma for at least 12 months.~* Subjects who have received a physician- prescribed asthma controller medication with medium or high dose ICS for at least 12 months; must be stable for at least 3 months prior to screening visit.~* At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.~* At enrolment, the subject must have a predicted normal value for the morning pre-bronchodilator FEV1\>50% and more than 1L.~* Evidence of asthma as documented by reversibility of FEV1 ≥12% and ≥200 mL in the previous 12 months prior to screening, or during the screening period prior to randomization.~* ACQ-6 score ≥ 1.5 during the screening period prior to randomization.~Principal Exclusion Criteria:~* Any clinically important pulmonary disease other than asthma.~* History of cancer.~* Hospitalization or required OCS for asthma exacerbation within 6 weeks of enrolment or \>3 exacerbations requiring OCS or hospitalization in the year prior to visit 1 or who had been intubated or admitted to ICU for asthma exacerbation in the year prior to enrolment.~* History of a clinically significant infection, including upper (URTI) or lower respiratory tract infection (LRTI), requiring treatment with antibiotics or antiviral medications finalized \<2 weeks before visit 1 or during the run-in period.~* Current smokers or subjects with smoking history ≥10 pack-yrs, including e-cigarettes. Former smokers with a smoking history of \<10 pack-yrs must have stopped for at least 6 months prior to visit 1, including e-cigarette use.~* History of chronic alcohol or drug abuse within 12 months prior to visit 1.~* Tuberculosis requiring treatment within 12 months prior to visit 1.~* History of known immunodeficiency disorder including a positive HIV test at visit 1, or the subject is taking antiretroviral medications as determined by medical history and/or subject's verbal report.~* History of anaphylaxis or documented immune complex disease (type III hypersensitivity reactions) following any biologic therapy Subject randomized in a previous Tezepelumab study or in a current study with another investigational product.~* Pregnant, breastfeeding or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (Type: EXPERIMENTAL): Tezepelumab subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).